Lamotrigine 25 mg Chewable Tablets, Non-Fasting

This study has been completed.
Sponsor:
Information provided by:
Teva Pharmaceuticals USA
ClinicalTrials.gov Identifier:
NCT00838136
First received: February 5, 2009
Last updated: September 1, 2009
Last verified: September 2009
Results First Received: June 30, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Bio-equivalence Study;   Intervention Model: Crossover Assignment;   Masking: Open Label
Condition: Healthy
Interventions: Drug: Lamotrigine 25 mg Chewable Tablets
Drug: Lamictal® 25 mg Chewable Tablets

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Lamotrigine (Test) First Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
Lamictal® (Reference) First Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period

Participant Flow for 2 periods

Period 1:   First Intervention
    Lamotrigine (Test) First     Lamictal® (Reference) First  
STARTED     16     16  
COMPLETED     16     16  
NOT COMPLETED     0     0  

Period 2:   Second Intervention
    Lamotrigine (Test) First     Lamictal® (Reference) First  
STARTED     16     16  
COMPLETED     16     15  
NOT COMPLETED     0     1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Lamotrigine (Test) First Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
Lamictal® (Reference) First Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period
Total Total of all reporting groups

Baseline Measures
    Lamotrigine (Test) First     Lamictal® (Reference) First     Total  
Number of Participants  
[units: participants]
  16     16     32  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     16     16     32  
>=65 years     0     0     0  
Gender  
[units: participants]
     
Female     2     0     2  
Male     14     16     30  
Race/Ethnicity, Customized  
[units: Participants]
     
Caucasian     13     14     27  
American Hispanic     3     0     3  
Black     0     1     1  
Asian     0     1     1  
Region of Enrollment  
[units: participants]
     
Canada     16     16     32  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Cmax - Maximum Observed Concentration   [ Time Frame: Blood samples collected over 120 hour period ]

2.  Primary:   AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)   [ Time Frame: Blood samples collected over 120 hour period ]

3.  Primary:   AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)   [ Time Frame: Blood samples collected over 120 hour period ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Manager, Biopharmaceutics
Organization: Teva Pharmaceuticals USA
phone: 1-866-384-5525
e-mail: clinicaltrialqueries@tevausa.com


No publications provided


ClinicalTrials.gov Identifier: NCT00838136     History of Changes
Other Study ID Numbers: 01304
Study First Received: February 5, 2009
Results First Received: June 30, 2009
Last Updated: September 1, 2009
Health Authority: Canada: Ethics Review Committee